Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Leases: 2019-2024

Historic Current Leases for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to $5.8 million.

  • C4 Therapeutics' Current Leases rose 10.37% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.2 million, marking a year-over-year increase of 10.37%. This contributed to the annual value of $5.8 million for FY2024, which is 10.63% up from last year.
  • As of FY2024, C4 Therapeutics' Current Leases stood at $5.8 million, which was up 10.63% from $5.2 million recorded in FY2023.
  • In the past 5 years, C4 Therapeutics' Current Leases registered a high of $5.8 million during FY2024, and its lowest value of $1.0 million during FY2020.
  • Over the past 3 years, C4 Therapeutics' median Current Leases value was $5.2 million (recorded in 2023), while the average stood at $5.2 million.
  • Data for C4 Therapeutics' Current Leases shows a peak YoY surged of 252.32% (in 2022) over the last 5 years.
  • C4 Therapeutics' Current Leases (Yearly) stood at $1.0 million in 2020, then increased by 28.02% to $1.3 million in 2021, then surged by 252.32% to $4.7 million in 2022, then rose by 11.04% to $5.2 million in 2023, then increased by 10.63% to $5.8 million in 2024.